Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Recruiting
Location: See all (52) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Locations
United States
Alabama
Mitchell Cancer Institute
NOT_YET_RECRUITING
Mobile
Arizona
Arizona Oncology Associates, P.C. - HOPE
NOT_YET_RECRUITING
Tucson
Florida
Cancer Specialists, LLC
NOT_YET_RECRUITING
Jacksonville
Minnesota
Minnesota Oncology Hematology, P.A.
NOT_YET_RECRUITING
Coon Rapids
New York
Cayuga Cancer Center
NOT_YET_RECRUITING
Ithaca
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
RECRUITING
New York
Ohio
Oncology Hematology Care Inc
NOT_YET_RECRUITING
Cincinnati
Texas
Texas Oncology - Paris
NOT_YET_RECRUITING
Fort Worth
US Oncology - Texas Oncology
NOT_YET_RECRUITING
Kyle
Other Locations
Australia
Liverpool Hospital
NOT_YET_RECRUITING
Liverpool
The Alfred Hospital
NOT_YET_RECRUITING
Melbourne
Austria
LKH - Universitätsklinikum der PMU Salzburg
NOT_YET_RECRUITING
Salzburg
Belgium
AZ Delta
NOT_YET_RECRUITING
Roeselare
Canada
Princess Margaret Cancer Centre - University Health Network
NOT_YET_RECRUITING
Toronto
China
Xuanwu Hospital Capital Medical University
NOT_YET_RECRUITING
Beijing
Hunan Cancer Hospital
NOT_YET_RECRUITING
Changsha
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING
Guangdong
Nanfang Hospital of Southern Medical University
NOT_YET_RECRUITING
Guangzhou
Gansu Provincial Cancer Hospital
NOT_YET_RECRUITING
Lanzhou
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING
Nanchang
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING
Shanghai
Taizhou Hospital of Zhejiang Province
NOT_YET_RECRUITING
Taizhou
Hematology Hospital of the Chinese Academy of Medical Sciences
NOT_YET_RECRUITING
Tianjin
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITING
Tianjin
Affiliated Cancer Hospital of Xinjiang Medical University
NOT_YET_RECRUITING
Ürümqi
The Affiliated Hospital of Xuzhou Medical College
NOT_YET_RECRUITING
Xuzhou
Henan Cancer Hospital
NOT_YET_RECRUITING
Zhengzhou
Croatia
University Hospital Center Zagreb
NOT_YET_RECRUITING
Zagreb
France
Centre Henri Becquerel
NOT_YET_RECRUITING
Rouen
Hungary
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
NOT_YET_RECRUITING
Budapest
Debreceni Egyetem
NOT_YET_RECRUITING
Debrecen
Ireland
Beaumont Hospital
NOT_YET_RECRUITING
Dublin
St. James's Hospital
NOT_YET_RECRUITING
Dublin
Italy
Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
NOT_YET_RECRUITING
Alessandria
Azienda Ospedaliera Universitaria Careggi
NOT_YET_RECRUITING
Florence
Presidio Ospedaliero Papardo
NOT_YET_RECRUITING
Messina
Fondazione IRCCS San Gerardo dei Tintori
NOT_YET_RECRUITING
Monza
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
NOT_YET_RECRUITING
Perugia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NOT_YET_RECRUITING
Rome
Tel Aviv Sourasky Medical Center
NOT_YET_RECRUITING
Tel Aviv
Azienda Ospedaliera S. Maria Di Terni
NOT_YET_RECRUITING
Terni
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
NOT_YET_RECRUITING
Verona
Japan
Tokai University Hospital
RECRUITING
Isehara
Poland
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
NOT_YET_RECRUITING
Brzozów
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
NOT_YET_RECRUITING
Bydgoszcz
Pratia Onkologia Katowice
NOT_YET_RECRUITING
Katowice
Instytut Hermatologii I Transfuzjologii
NOT_YET_RECRUITING
Warsaw
Spain
Hospital Universitario Marques De Valdecilla
NOT_YET_RECRUITING
Santander
Hospital Universitario Virgen Del Rocio
NOT_YET_RECRUITING
Seville
United Kingdom
Castle Hill Hospital
NOT_YET_RECRUITING
Hull
St James's University Hospital
RECRUITING
Leeds
GenesisCare
NOT_YET_RECRUITING
Newmarket
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2026-03-09
Estimated Completion Date: 2032-12
Participants
Target number of participants: 150
Treatments
Experimental: Pirtobrutinib (Arm A)
Participants receive pirtobrutinib orally
Experimental: Idelalisib (Arm B)
Participants receive idelalisib orally
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company